Back
Compare AU
Compare CURE vs. IPAY
Compare shares and ETFs on the ASX that you can trade on Pearler.
Overview
When it comes to investing in the Australian stock market, Exchange-Traded Funds (ETFs) are a popular choice. Two well-known options in the Australian Securities Exchange (ASX) are the Global X S&P Biotech ETF (CURE) and the --- (---). In this comparison, we'll delve into these ETFs across various dimensions to help you make an informed investment decision.
Community Stats
CURE | --- | |
|---|---|---|
Popularity | Low | N/A |
Pearlers invested | 74 | 0 |
Median incremental investment | $652.50 | - |
Median investment frequency | Monthly | N/A |
Median total investment | $1,336.80 | $0 |
Average age group | > 35 | N/A |
Key Summary
CURE | --- | |
|---|---|---|
Strategy | CURE.AX was created on 2018-11-08 by Global X. The fund's investment portfolio concentrates primarily on health care equity. The Fund aims to provide investors with a return that (before fees and expenses) tracks the performance of the S&P Biotechnology Select Industry Index. | N/A |
Top 3 holdings | Alnylam Pharmaceuticals Inc (2.61 %) Insmed Inc (2.59 %) Exelixis Inc (2.55 %) | AMERICAN EXPRESS CO (6.43 %) PAYPAL HOLDINGS INC (6.24 %) VISA INC (6.13 %) |
Top 3 industries | Health Care (100.00 %) Other (10.24 %) | |
Top 3 countries | United States (97.17 %) Switzerland (1.51 %) United Kingdom of Great Britain and Northern Ireland (1.16 %) | |
Management fee | 0.45 % | N/A |
Key Summary
CURE | --- | |
|---|---|---|
Issuer | Global X | N/A |
Tracking index | S&P Biotechnology Select Industry | N/A |
Asset class | ETF | Stock |
Management fee | 0.45 % | N/A |
Price | $43.92 | $-- |
Size | $30.164 million | N/A |
10Y return | N/A | N/A |
Annual distribution yield (5Y) | 7.07 % | - % |
Market | ASX | ASX |
First listed date | 12/11/2018 | N/A |
Purchase fee | $6.50 | $6.50 |
Community Stats
CURE | --- | |
|---|---|---|
Popularity | Low | N/A |
Pearlers invested | 74 | 0 |
Median incremental investment | $652.50 | - |
Median investment frequency | Monthly | N/A |
Median total investment | $1,336.80 | $0 |
Average age group | > 35 | N/A |
Pros and Cons
CURE | --- | |
|---|---|---|
Pros |
|
|
Cons |
|
|
CURE | --- |
|---|---|
Exposure to more markets and sectors | Exposure to 1 market and 1 sector only |
Lower price growth | Higher price growth |
Higher dividend/distribution yield | Lower dividend/distribution yield |